• Home
  • About KinaseCentral

Kinase News

Entries RSS | Comments RSS
  • Blogroll

    • CrimsonCanary.com
    • KinaseCentral
    • PharmaCompanyPipelines
  • Tags

    AstraZeneca aurora Avastin bayer Bcr-Abl bevacizumab BMS c-kit cetuximab EGFR ErbB-2 ErbB2 erbitux Exelixis Genentech GlaxoSmithKline Gleevec GSK HER1 HER2 IGF-1R Imatinib ImClone JAK2 kinase Merck-Serono Met mTOR multikinase Nexavar Novartis onyx PDGF Pfizer phase I Phase II phase iii PI3K Preclinical regulatory Research Roche sorafenib VEGF VEGFR2
  • Providing a resource for information on kinase inhibitors

Roche to initiate Phase II trial of IGF-1R MAb R1507 in NSCLC

Posted on September 29, 2008 by crimsoncanary

Roche and Genmab are preparing to initatea phase II trial of IGF-1R MAb R1507 in NSCLC in combination with tarceva

Filed under: Uncategorized | Tagged: erlotinib, Genmab, IGF-1R, IGF-R1, Monoclonal, R-1507, R1507, Roche, Tarceva

« ImClone initiate randomized Phase II trial of IMC-A12 in breast cancer Astex and Cancer Research UK collaborate on PKB inhibitor »
  • Calendar

    • September 2008
      M T W T F S S
      « Aug   Oct »
      1234567
      891011121314
      15161718192021
      22232425262728
      2930  
  • Blogroll

    • CrimsonCanary.com
    • KinaseCentral
    • PharmaCompanyPipelines

Blog at WordPress.com. Theme: Digg 3 Column by WP Designer